Entry

D00896                      Drug

Name

Efavirenz (JAN/USP/INN);
Sustiva (TN)

Abbr

EFV

Product

SUSTIVA (Bristol-Myers Squibb Pharma Company)

Generic

EFAVIRENZ (Aurobindo Pharma Limited), EFAVIRENZ (Aurobindo Pharma Limited), EFAVIRENZ (Camber Pharmaceuticals), EFAVIRENZ (Cipla USA), EFAVIRENZ (Golden State Medical Supply), EFAVIRENZ (Mylan Pharmaceuticals), EFAVIRENZ (REMEDYREPACK), EFAVIRENZ (REMEDYREPACK), EFAVIRENZ (REMEDYREPACK), EFAVIRENZ (Rising Pharmaceuticals), EFAVIRENZ (Strides Pharma), EFAVIRENZ (Strides Pharma Science Limited), EFAVIRENZ (XLCare Pharmaceuticals)

Formula

C14H9ClF3NO2

Exact mass

315.0274

Mol weight

315.675

Structure

Simcomp

Class

Antiviral
DG01889  Non-nucleoside reverse transcriptase inhibitor (NNRTI)
DG03107  Anti-HIV agent
  DG01656  HIV reverse transcriptase inhibitor
Metabolizing enzyme substrate
DG02919  CYP2B6 substrate
DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Metabolizing enzyme inducer
DG02891  CYP2B6 inducer
DG02853  CYP3A/CYP3A4 inducer
  DG01635  CYP3A4 inducer

Remark

Same as:

C08088

Therapeutic category:

6250

ATC code:

J05AG03

Product:

D00896<JP/US>

Product (mixture):

D10851<US> D11392<US>

Efficacy

Antiviral, Reverse transcriptase inhibitor

Disease

HIV-1 infection [DS:H01563]

Target

HIV-1 reverse transcriptase [KO:K24802]

Pathway

ko03230

Viral genome structure

ko03240

Viral replication

ko03250

Viral life cycle - HIV-1

Metabolism

Enzyme: CYP3A4 [HSA:1576], CYP2B6 [HSA:1555]

Interaction

CYP induction: CYP2B6 [HSA:1555], CYP3A4 [HSA:1576]

Structure map

map07053

Anti-HIV agents

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AG Non-nucleoside reverse transcriptase inhibitors
     J05AG03 Efavirenz
      D00896  Efavirenz (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antivirals
  Anti-HIV Agents, Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI)
   Efavirenz
    D00896  Efavirenz (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D00896  Efavirenz (JAN/USP/INN)
Drug groups [BR:br08330]
Antiviral
  DG01889  Non-nucleoside reverse transcriptase inhibitor (NNRTI)
   D00896  Efavirenz
  DG03107  Anti-HIV agent
   DG01656  HIV reverse transcriptase inhibitor
    D00896  Efavirenz
Metabolizing enzyme substrate
  DG02919  CYP2B6 substrate
   D00896  Efavirenz
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D00896  Efavirenz
Metabolizing enzyme inducer
  DG02891  CYP2B6 inducer
   D00896  Efavirenz
  DG02853  CYP3A/CYP3A4 inducer
   DG01635  CYP3A4 inducer
    D00896  Efavirenz
Drug classes [BR:br08332]
Antiviral
  DG03107  Anti-HIV agent
   D00896  Efavirenz
Antimicrobials [BR:br08307]
Antivirals
  Genome replication inhibitor
   HIV reverse transcriptase inhibitor
    D00896  Efavirenz (JAN/USP/INN) <JP/US>
Antimicrobials abbreviations [BR:br08327]
Antivirals
  Genome replication inhibitor
   HIV reverse transcriptase inhibitor
    D00896  Efavirenz (JAN/USP/INN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D00896
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D00896
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
  D00896

Other DBs

CAS:	154598-52-4

PubChem:

7847960

ChEBI:

119486

PDB-CCD:

EFZ[PDBj]

LigandBox:

D00896

NIKKAJI:

J727.577C

KCF data

ATOM        21
            1   C1z C    22.0907  -17.8033
            2   C8y C    20.8724  -18.4968
            3   C3b C    23.0815  -16.8124
            4   O7x O    23.3087  -18.5085
            5   C1d C    20.8724  -17.1096
            6   C8y C    20.8724  -19.8957
            7   C8x C    19.6776  -17.7974
            8   C3b C    24.0607  -15.8216
            9   C7x C    23.2970  -19.9074
            10  X   F    19.4676  -17.1039
            11  X   F    20.4935  -15.7516
            12  X   F    21.8457  -16.1130
            13  N1x N    22.0790  -20.6069
            14  C8x C    19.6776  -20.6009
            15  C8y C    18.4534  -18.4968
            16  C1y C    25.0457  -14.8248
            17  O6a O    24.5036  -20.6126
            18  C8x C    18.4534  -19.8957
            19  X   Cl   17.2352  -17.7974
            20  C1x C    26.3922  -14.4634
            21  C1x C    25.3954  -13.4783
BOND        23
            1     1   2 1
            2     1   3 1 #Down
            3     1   4 1
            4     1   5 1 #Up
            5     2   6 2
            6     2   7 1
            7     3   8 3
            8     4   9 1
            9     5  10 1
            10    5  11 1
            11    5  12 1
            12    6  13 1
            13    6  14 1
            14    7  15 2
            15    8  16 1
            16    9  17 2
            17   14  18 2
            18   15  19 1
            19   16  20 1
            20   16  21 1
            21    9  13 1
            22   15  18 1
            23   20  21 1